B3B

Home/B3B

About B3B

This author has not yet filled in any details.
So far B3B has created 198 blog entries.

Plan to Fabricate a Genome Raises Questions on Designer Humans

Antonio Regalado of MIT Technology Review writes about the recent proposal of some scientists to create a human genome "from scratch" - the intro of the feature: "A proposal by a group of scientists and businesspeople to synthesize a human genome from scratch is attracting sharp criticism for dodging the big ethical questions such a step [...]

June 2nd, 2016|

Why Sarepta’s Shares Slumped

From Dan Caplinger/Motley Fool: "Sarepta Therapeutics plunged 27% after the Food and Drug Administration released information that could threaten the company's ability to maximize profits if its treatment for Duchenne muscular dystrophy eventually receives FDA approval. The FDA's recommendations centered on its compassionate use policy, saying companies generally could only get paid to offset its [...]

June 2nd, 2016|

A Machine That Spits Out Drugs In A Whole New Way

Intro of article/feature by Martha Bebinger, WBUR: "In a lab at the Massachusetts Institute of Technology, all the work that happens in a vast pharmaceutical manufacturing plant happens in a device the size of your kitchen refrigerator. And it’s fast. This prototype machine produces 1,000 pills in 24 hours, faster than it can take to [...]

May 26th, 2016|

Communicating the Good, Bad & Ugly for CMOs and R&D Leaders

Dr. Mark Weinberg, Halloran’s CMO and Managing Director, was interviewed by Valerie Bowling of PharmaTalk Radio & The Conference Forum on May 16, 2016. The below radio interview description is was originally posted on BlogTalkRadio.com. More information and details on the Halloran Consulting site

May 19th, 2016|

Celgene, Agios in $1B+ Metabolic Immuno-Oncology Alliance

Excerpts of coverage: Bloomberg Bay State Biotech Report: Celgene’s New Agios Cancer Drug Deal: http://assets.bwbx.io/av/users/iqjWHBFdfxIU/vrCdnmNfE3No/v2.mp3 GEN - "Celgene and Agios Pharmaceuticals will partner to develop metabolic immuno-oncology therapies, under a strategic alliance that could generate about $1 billion-plus for Agios.The companies said they will discover, develop, and commercialize new treatments focused on altering the [...]

May 18th, 2016|

A Century of Innovation

As part of a focus series on Kendall Square, the Boston Globe has put together a timeline feature that chronicles innovation developments that have shaped the Boston/Cambridge area since 1916 - the intro: "Pinpointing the most pivotal moments in Kendall Square history is like naming the all-time greatest Celtics players. Tough choices. For the Celtics, Bird [...]

May 6th, 2016|

Boston is #1: GEN’s Annual “Top 10 U.S. Biopharma Clusters”

GEN has put out its annual "Top 10 U.S. Biopharma Clusters" list, and the regions of Big3Bio help lead the way, with the Greater Boston area again coming in at #1. The ranking criteria: NIH funding—Taken from the publicly available NIH RePORT database, for the current federal fiscal year, from its start on October 1, 2015, through [...]

May 2nd, 2016|

Why I’m Sticking With Sarepta

From CNBC: "Shares of Sarepta Pharmaceutical sinking after the FDA rejected the company's experimental drug to treat Muscular Dystrophy. Despite the drop, "Halftime Report" expert Jon Najarian is bullish on the stock long-term. Najarian sees the sell-off as a buying opportunity calling it "the gift that keeps on giving...I thought last week's selloff was overdone [...]

April 27th, 2016|

Cell Therapy Manufacturing Q&A – The Big3Bio Interview with Barbara Nelsen

Nelsen Biomedical is a life sciences consulting firm specializing in strategic development for companies with innovative technologies, involved in emerging industries, and focused on expanding markets. Founded in 2011 by Barbara Nelsen, Ph.D., Nelsen Biomedical harnesses the energy, leadership and entrepreneurship of to Minneapolis, Boston and Chicago life sciences communities to drive strategic growth for [...]

April 25th, 2016|
X